AbbVie

ABBV · NYSE · USD

$262.82+1.11%+$2.89

Close · October 2, 2026

At a glance

Revenue growth: +8.57%; 2025 vs 2024
Net income growth: −1.22%; 2025 vs 2024
Net margin: 6.9%; 2024: 7.6%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Annual
Item	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Total revenue	61,160	56,334	54,318	58,054	56,197	45,804	33,266	32,753	28,216	25,638
Cost of revenue	17,357	16,689	16,826	16,527	17,314	15,257	7,439	7,718	6,688	5,793
Gross profit	43,803	39,645	37,492	41,527	38,883	30,547	25,827	25,035	21,528	19,845
Selling, general and administrative	13,644	14,099	12,419	14,584	11,872	9,867	6,763	7,353	6,248	5,837
Research and development	9,068	8,131	7,038	6,487	6,820	6,003	5,377	5,259	5,007	4,385
Operating income	21,115	17,422	18,214	20,228	19,759	14,677	14,247	11,923	10,273	9,623
EBIT	21,115	17,422	18,214	20,228	19,759	14,677	14,247	11,923	10,273	9,623
EBITDA	29,254	25,808	26,912	28,695	28,280	21,148	16,264	13,688	11,774	10,812
Interest expense	2,893	2,808	2,224	2,230	2,423	2,454	1,784	1,348	1,150	1,047
Pre-tax income	6,597	3,716	6,250	13,477	12,989	3,398	8,426	5,197	7,727	7,884
Income tax	2,364	-570	1,377	1,632	1,440	-1,224	544	-490	2,418	1,931
Net income	4,226	4,278	4,863	11,836	11,542	4,616	7,882	5,687	5,309	5,953
Net income to common shareholders	4,186	4,238	4,820	11,782	11,468	4,556	7,842	5,657	5,283	5,923
Basic EPS	2.37	2.40	2.73	6.65	6.48	2.73	5.30	3.67	3.31	3.65
Diluted EPS	2.36	2.39	2.72	6.63	6.45	2.72	5.28	3.66	3.30	3.63
Average shares (basic)	1,769	1,769	1,768	1,771	1,770	1,667	1,481	1,541	1,596	1,622
Average shares (diluted)	1,773	1,773	1,773	1,778	1,777	1,673	1,484	1,546	1,603	1,631
Dividend per share	6.65	6.29	5.99	5.71	5.31	4.84	4.39	3.95	2.63	2.35